Terns Pharmaceuticals, Inc. Capital Stock Change

Capital Stock Change of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital Stock Change growth rates and interactive chart.


Highlights and Quick Summary

  • Capital Stock Change for the quarter ending December 31, 2021 was $16 Thousand (a -97.99% decrease compared to previous quarter)
  • Year-over-year quarterly Capital Stock Change decreased by -99.99%
  • Annual Capital Stock Change for 2021 was $914 Thousand (a -98.68% decrease from previous year)
  • Annual Capital Stock Change for 2020 was $69.5 Million (a 267196.15% increase from previous year)
  • Annual Capital Stock Change for 2019 was $26 Thousand (a -99.97% decrease from previous year)
  • Twelve month Capital Stock Change ending December 31, 2021 was $1 Million (a -1.57% decrease compared to previous quarter)
Trailing Capital Stock Change for the last four month:
31 Dec '21 30 Sep '21
$1 Million $1.02 Million
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital Stock Change of Terns Pharmaceuticals, Inc.

Most recent Capital Stock Changeof TERN including historical data for past 10 years.

Interactive Chart of Capital Stock Change of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Capital Stock Change for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.02 $0.8 $0.1 $135.33 $0.91
2020 $69.47 $0.03 $-0.03 $69.5
2019 $0.03
2018 $87.66

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.